NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LXRX shares have decreased by 13.7% and is now trading at $1.96.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.02. The biopharmaceutical company had revenue of $9.16 million for the quarter, compared to analyst estimates of $8.70 million. Lexicon Pharmaceuticals had a net margin of 12.26% and a return on equity of 50.16%.
View Lexicon Pharmaceuticals' earnings history.

5 Wall Street analysts have issued 1 year price targets for Lexicon Pharmaceuticals' shares. Their forecasts range from $2.10 to $3.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $2.70 in the next year. This suggests a possible upside of 37.8% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals.

Media headlines about LXRX stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near future.
View the latest news about Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 11,370,000 shares, an increase of 9.3% from the June 30th total of 10,400,000 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is currently 8.2 days. Approximately 11.0% of the company's stock are sold short.
View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Geron (GERN), Orexigen Therapeutics (OREX), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Micron Technology (MU).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.36%), Strs Ohio (0.22%), Envestnet Asset Management Inc. (0.08%), UBS Group AG (0.03%), ProShare Advisors LLC (0.02%) and Diversified Trust Co (0.02%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Strs Ohio, Wedbush Securities Inc., Diversified Trust Co, Investors Financial Group LLC, UBS Group AG, and ProShare Advisors LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $1.96.

Lexicon Pharmaceuticals has a market capitalization of $209.94 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.